nature portfolio

Corresponding author(s):	Qing-Jun Meng and Judith Hoyland
Last updated by author(s):	Aug 24, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_				
Ç.	tat	ŀις	tπ	\sim

n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
x	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
X	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
x	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

LumiCycle (Actimetrics) - bioluminescence recording; Zeiss software Aim version 4.2 -calcium imaging; Zeiss Zen2 software - Venus reporter fluorescence; Image Studio (Li-Cor) - fluorescent western blot imaging

Data analysis

LumiCycle Analysis 2.31 (Actimetrics) - bioluminescence; GraphPad Prism 9 - basic statistical analysis; Cell Tracker (version 0.6) - Venus reporter fluorescence analysis; RNAseq analysis: FastQC 0.11.9, Trimmomatic_0.39, STAR_2.7.7a, DESeq2_1.28.1, scikit-learn 1.1.0, MetaCycle_1.2.0, Ingenuity Pathway Analysis (Qiagen), Image Studio Lite 5.2 (Li-Cor)- fluorescent western blot imaging

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

RNAseq raw data were deposited to ArrayExpress repository (accession no. E-MTAB-11040 for osmotic stress in primary chondrocytes and E-MTAB-12877 for treadmill running tissues). Circadian cartilage RNAseq dataset E-MTAB-3428 was used for comparison with the treadmill running dataset. Mouse reference genome

(mm10/GRCm38 was	used for mapping	RNAseq reads. All other data is contained within the manuscript and supplementary information.			
Human resea	arch partic	sipants			
Policy information a	about <u>studies in</u>	volving human research participants and Sex and Gender in Research.			
Reporting on sex an	nd gender	N/A			
Population characte	eristics	N/A			
Recruitment		N/A			
Ethics oversight		N/A			
Note that full information	ote that full information on the approval of the study protocol must also be provided in the manuscript.				
Field-spe	cific re	oorting			
•		the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences	Ве	havioural & social sciences			
For a reference copy of th	he document with al	I sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
<u>Life scien</u>	ices stu	dy design			
All studies must disc	close on these p	oints even when the disclosure is negative.			
Sample size	dx.doi.org/10.11	re based on similar experiments done with similar cell lines and explants (https://doi.org/10.1172/JCI82755, http://36/annrheumdis-2016-209428 and https://doi.org/10.1016/j.matbio.2023.07.002). We did not perform power estimates g the data and performed statistical tests after data collection.			
Data exclusions	No data was excl	uded from analysis.			
Replication	6 mice per condition were used in treadmill running experiments. Between 3-6 mice per condition were used in in tissue explant experiments as indicated in figure legends. All experiments were successfully replicated and results showed consistency.				
Randomization	Samples and animals were randomly assigned to control and treatment conditions.				
Blinding	Investigators were not blinded during data collection and analysis. Experimental conditions (e.g. young vs. old mice or running vs. sedentary) and data analysis methods did not allow for blinding.				
We require informatic system or method liste Materials & exp n/a Involved in the x Antibodies x Eukaryotic of x Palaeontolo	perimental sy e study cell lines ogy and archaeolo	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging			
Animals and other organisms Clinical data					
Dual use research of concern					

Antibodies

Antibodies used

All primary antibodies were purchased from Cell Signaling Technology ERK1/2 (#4695), pThr202/pTyr204 ERK1/2 (#4370), p38 (#8690), pThr180/pTyr182 p38 (#4511), GSK3 β (#12456), pSer9 GSK3 β (#5558), except for pSer389 GSK3 β (14850-1-AP) which was purchased from Proteintech and α Tubulin (T9026) purchased from Sigma Aldrich. Secondary antibodies: LI-COR

IRDye® 800CW Goat anti-Mouse IgG (926-32210) and IRDye® 680RD Goat anti-Rabbit IgG (926-68071).

Validation

Antibodies were validated by manufacturer by either knock-down of target, overexpression of target or treatments inducing expression/phosphorylation of target. All antibodies were validated by manufacturer for the species (Human, Mouse) and application (western blotting) used in this study. Detected protein size was checked against uniprot database and manufacturers information sheet.

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

Cell line source(s)

Primary chondrocytes were isolated from PER2::Luc reporter mice (Yoo, S.H., et al. PNAS 2013) and PER2::Venus reporter mice (Smyllie, N.J, et al. Curr Bio 2016). Immortalised human nucleus pulposus (NP) cell line NP115 was described previously

(van den Akker, G.G., et al. Arthritis Res Ther, 2014). Immortalized rat NP cells was described previously (Oh CD, et al. Spine

(Phila Pa 1976) 2016).

Authentication Primary chondrocytes were isolated and phenotyped according to published protocol (Gosset M, et al. Nat Protoc 2008).

Particularly at confluence primary mouse chondrocytes exhibit the typical chondrocyte morphology, with a rounded or polygonal shape and granular cytoplasm. Expression of chondrocyte markers Col2a1 and Acan was confirmed by qPCR using

gene and species specific TaqMan probes.

Mycoplasma contamination Cells are routinely tested. No contamination was found.

Commonly misidentified lines

(See <u>ICLAC</u> register)

No commonly misidentified cell lines were used in this study.

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals PER2::Luc reporter mice (Yoo, S.H., et al. PNAS 2013) and PER2::Venus reporter mice (Smyllie, N.J, et al. Curr Bio 2016) were used at

4-8 weeks of age. Additionally PER2::Luc reporter mice at 12 months old were used for ageing experiment. Mice were housed in Tecniplast Green Line cages and racks at 20-22°C and average 60% humidity, with standard rodent chow available ad libitum and

under 12:12 hr light dark schedule (light on at 7 am; light off at 7 pm).

Wild animals No wild animals were used.

Reporting on sex Mice of both sexes were used in experiments

Field-collected samples none

Ethics oversight All animal studies were performed in accordance with the 1986 UK Home Office Animal Procedures Act. Approval was provided by

the University o Manchester's Animal Welfare and Ethical Review Board (AWERB).

Note that full information on the approval of the study protocol must also be provided in the manuscript.